Literature DB >> 27708870

Thrombocytopenia caused by albendazole in a patient with Sjögren's syndrome: A case report.

Pınar Açıkgöz1, İbrahim Halil Türkbeyler2, Yavuz Pehlivan3.   

Abstract

Sjögren's syndrome (SS) is an autoimmune disease characterised by a chronic inflammatory response mainly localised to the lachrymal and salivary glands. Haematological abnormalities are common, although they rarely have clinical significance. Here, we report a patient with SS and thrombocytopenia caused by albendazole. Haematological abnormalities such as thrombocytopenia are seen in approximately 5-15% of SS patients; however, this disease is usually asymptomatic and can often be recovered to normal levels with corticosteroids. If it is not, we should keep in mind other reasons for the thrombocytopenia, such as drug use.

Entities:  

Keywords:  Sjögren’s syndrome; Thrombocytopenia; albendazole

Year:  2014        PMID: 27708870      PMCID: PMC5042261          DOI: 10.5152/eurjrheum.2014.009

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  11 in total

Review 1.  A review and update of Sjögren's syndrome: manifestations, diagnosis, and treatment.

Authors:  S Carsons
Journal:  Am J Manag Care       Date:  2001-09       Impact factor: 2.229

Review 2.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

3.  A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study.

Authors:  K Asmussen; V Andersen; G Bendixen; M Schiødt; P Oxholm
Journal:  J Intern Med       Date:  1996-06       Impact factor: 8.989

4.  Aplastic anemia during treatment with albendazole.

Authors:  F J Fernández; F F Rodríguez-Vidigal; V Ledesma; Y Cabanillas; J M Vagace
Journal:  Am J Hematol       Date:  1996-09       Impact factor: 10.047

5.  Albendazole-induced amegakaryocytic thrombocytopenic purpura.

Authors:  B O Yildiz; I C Haznedaroğlu; L Cöplü
Journal:  Ann Pharmacother       Date:  1998 Jul-Aug       Impact factor: 3.154

6.  Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance.

Authors:  U Steiger; J Cotting; J Reichen
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

7.  Methyldopa-induced reversible immune thrombocytopenia.

Authors:  R G Pai; S M Pai
Journal:  Am J Med       Date:  1988-07       Impact factor: 4.965

8.  Death related to albendazole-induced pancytopenia: case report and review.

Authors:  Lucie Opatrny; Roger Prichard; Linda Snell; J Dick Maclean
Journal:  Am J Trop Med Hyg       Date:  2005-03       Impact factor: 2.345

9.  Sulfasalazine-induced immune thrombocytopenia.

Authors:  L Cantarini; I Tinazzi; D Biasi; A Fioravanti; M Galeazzi
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

10.  Haematological manifestations of primary Sjögren's syndrome: a clinicopathological study.

Authors:  R Ramakrishna; K Chaudhuri; A Sturgess; A Manoharan
Journal:  Q J Med       Date:  1992-07
View more
  1 in total

1.  Fatal pancytopenia due to albendazole treatment for strongyloidiasis.

Authors:  Fanfan Xing; Haiyan Ye; Jin Yang; Jasper Fuk-Woo Chan; Wai-Kay Seto; Pearl Ming-Chu Pai; Kwok-Yung Yuen; Derek Ling-Lung Hung
Journal:  IDCases       Date:  2018-04-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.